Hepatitis C Information Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatments here at Hepatitis-Central.com.

Hep C information
Free Newsletter
Hepatitis C Newsletter
We value your privacy. We will not rent your email to anyone.
HEPATITIS NEWS
The top stories compiled from over 5,500 sources, updated every 15 minutes

Hepatitis E confirmed in Gulu
Gulu Hepatitis E has been confirmed in Odeke Sub-county in Gulu District. The District Health Educator Mr Okot Lukaki said three cases have been reported. He said a task force has been created to ensure cleanliness especially in the camps. Mr Lukaki said

New hepatitis C virus vaccines study findings reported from Research Center for Infectious Diseases
- (NewsRx.com) -- Fresh data on hepatitis C virus are presented in the report 'Open-label trial of therapeutic immunization with oral V-5 Immunitor (V5) vaccine in patients with chronic hepatitis C.' According to recent research published in the journal

Hepatitis E Risk 'On the Rise'
(UN Integrated Regional Information Networks/All Africa Global Media via COMTEX News Network) -- More people are at risk of contracting the Hepatitis E virus (HEV) in the northern Uganda district of Kitgum, according to a surveillance health report. 'The

UPDATES AND COMMENTARY RSS Feed

Good News for Non-Responders to HCV Combination Therapy
A Phase 3 trial evaluating ZADAXIN® (thymalfasin) as a potential third component for Hepatitis C traditional combination therapy has just been completed. Although the data is currently being analyzed and won't be available until later in the year, the lead...

Purer, Less Costly Interferon for Hepatitis C and B Treatment
The Taiwan-based biopharmaceutical company PharmaEssentia Corp. is testing P1101, its third-generation PEG-interferon-alpha drug candidate. Because it is a longer-lasting, purer interferon that is less costly to produce, P1101 could enhance the treatment options for Hepatitis C and B....

New Technology May Help Treat Hepatitis
While pharmaceutical companies are racing to find safer, more effective treatments for viral Hepatitis C and B, physicists from Arizona have a unique perspective on accomplishing the same goal. Learn how these scientists believe the virus could be rendered harmelss...

Bull Acad Natl Med 1996 Jun;180(6):1253-1262
[Epidemiology of infections linked to hepatitis C virus in France].


[Article in French]
Roudot-Thoraval F

Departement de Sante Publique, CHU Henri Mondor, Creteil.

In France, the population of adult carriers of anti-HCV antibodies has been estimated about 600,000, but only 10 to 15% are aware of the diagnosis. Two major sources of infection have been identified : transfusion and intravenous drug use, accounting for 60% of HCV infections. In contrast, sexual or household transmission, mother-to-infant transmission or occupational exposure account for a small part of the HCV epidemic. In about 15% of cases, a nosocomial exposure is questioned, probably related to an insufficient decontamination of medical devices. Finally, no source of infection can be recognized in about 20% of infected patients. Among them, many have spent a long stay in high HCV prevalence areas, suggesting local percutaneous exposures. The diagnosis of chronic hepatitis C is often made late in the course of the disease, an average of 10 years after exposure. At this time, a cirrhosis is present in about 20% of the patients. The frequency of cirrhosis depends on the duration of the HCV infection, and probably also on the source of transmission, independently of the duration of the disease. Thus, it has been observed that cirrhosis was more frequent in transfusion recipients than in intravenous drug users. Such a difference could be related to different HCV genotypes in the different groups at risk. The genotype 1b has been found predominant in transfusion recipients whereas genotype 3a was more frequent in drug users. Recently, a slight modification in the relative frequency of the different genotypes, mainly spreading and increased frequency of genotype 3a could lead to a modified epidemiology of HCV infection. The consequences of such modifications need to be evaluated.

PMID: 8991607, UI: 97103848

table Of Contents

  Hep C information

Information at this website is for educational purposes only; statements about products and health conditions
have not been evaluated by the U.S. Food & Drug Administration.

©1994-2008 Hepatitis-Central.com
Updated 04 Jul 2008